Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med

Volastra Therapeutics has boosted its pipeline and its bank balance in one day, securing its first clinical-stage asset courtesy of a Big Pharma licensing deal as well as gathering $60 million in financing to focus on human trials.